Compare W W Grainger Inc (GWW) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Medpace Holdings Inc — how do they compare? W W Grainger Inc trades at $1,398.78 (market cap $64.75B), while Medpace Holdings Inc trades at $534.54 (market cap $15.11B). The key difference: W W Grainger Inc is far larger — about 4.3× Medpace Holdings Inc's market cap, and W W Grainger Inc pays a 0.68% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| GWW | MEDP | |
|---|---|---|
Market Cap | $64.75B | $15.11B |
Sector | Technology | Technology |
52-Week High | $1.39K | $620.59 |
52-Week Low | $918.18 | $308.88 |
Enterprise Value | $66.84B | $14.58B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,391.07, up 1.46% with strong technical momentum and bullish moving averages. The company reported solid Q1 2026 earnings of $11.65 per share, beating estimates, and raised full-year guidance. With revenue growth to $18.4B and net profit margin improving to 9.69%, fundamentals remain robust despite elevated valuation multiples.
Outlook remains positive with analyst consensus price target of $1,260 offering modest upside. Key risks include high P/E ratio of 36.88 and competitive pressures in industrial distribution. The stock presents a quality growth opportunity but requires monitoring of valuation sustainability amid economic uncertainties.
MEDP trades at $539.39, up 0.6% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue grew to $2.53B in 2025, and net income margins remain strong at 17.19%, though valuation ratios like P/E of 33.31 suggest premium pricing. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook: MEDP shows robust profitability and growth potential, but high valuations and legal risks warrant caution. Analyst consensus is mixed with a $497 price target below current levels, indicating limited upside. Key catalysts include Q2 2026 earnings on July 22, 2026, which could drive momentum if results exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
